Page last updated: 2024-12-07
1-nitroso-5,6-dihydrouracil
Description
## 1-Nitroso-5,6-dihydrouracil: A Versatile Research Tool
1-Nitroso-5,6-dihydrouracil (also known as **DHU-NO**) is a **nitrosated derivative** of **5,6-dihydrouracil**. This molecule holds significant importance in research due to its diverse applications, particularly in the fields of:
**1. DNA Modification and Damage Research:**
* **Nitrosating Agent:** DHU-NO acts as a **potent nitrosating agent**, which means it can transfer a nitroso group (NO) to other molecules. This property makes it valuable for studying **nitrosative stress** and its role in DNA damage.
* **DNA Adduct Formation:** DHU-NO reacts with DNA, forming **adducts**, which are chemical modifications to DNA. These adducts can disrupt DNA replication and repair processes, leading to mutations and potentially cancer development. Studying these adducts helps researchers understand the mechanisms of DNA damage caused by nitrosating agents.
**2. Biomarker for Nitrosative Stress:**
* **Early Detection:** DHU-NO has been identified as a potential **biomarker for nitrosative stress**. Monitoring its levels in biological samples can help researchers assess exposure to nitrosating agents and identify individuals at risk for nitrosative stress-related diseases.
**3. Drug Development and Therapy:**
* **Targeted Therapy:** DHU-NO's ability to modify DNA and its role in nitrosative stress makes it an interesting molecule for drug development. Researchers are exploring its potential as a therapeutic agent for treating certain types of cancers and other diseases associated with DNA damage.
**4. Chemical Biology Studies:**
* **Probing Chemical Reactions:** DHU-NO is useful as a **probe** in chemical biology studies. It can be used to investigate the reactivity of other molecules and gain insight into the mechanisms of chemical reactions.
**Overall, 1-Nitroso-5,6-dihydrouracil is a valuable research tool due to its unique properties and diverse applications. It plays a crucial role in advancing our understanding of DNA damage, nitrosative stress, and the development of novel therapeutic strategies.**
**Note:** While DHU-NO holds promise in research, its potential toxicity and the complexity of its biological interactions require further careful study and evaluation before it can be used in clinical applications.
N-nitrosodihydrouracil: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 85598 |
SCHEMBL ID | 3340184 |
MeSH ID | M0058616 |
Synonyms (25)
Synonym |
nsc-90999 |
16813-36-8 |
wln: t6nvmvtj ano |
2,3h)-pyrimidinedione, dihydro-1-nitroso- |
1-nitroso-5,6-dihydrouracil |
nsc90999 |
NCIOPEN2_001450 |
1-nitrosodihydropyrimidine-2,4(1h,3h)-dione |
ndhu |
uracil, 5,6-dihydro-1-nitroso- |
2,4(1h,3h)-pyrimidinedione, dihydro-1-nitroso- |
ccris 1563 |
nsc 90999 |
brn 0779636 |
no-dhu |
hydrouracil, 1-nitroso- |
1-nitroso-1,3-diazinane-2,4-dione |
AKOS006275941 |
3my7h215cv , |
unii-3my7h215cv |
5-24-05-00276 (beilstein handbook reference) |
SCHEMBL3340184 |
n-nitrosodihydrouracil |
DTXSID6020989 |
dihydro-1-nitroso-2,4(1h,3h)-pyrimidinedione |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (80.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.38 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |